Otsuka America Pharmaceutical announced that BreathTek UBT for H. Pylori Kit may be administered to patients who are taking proton-pump inhibitors (PPIs).
BreathTek UBT Kit is a non-invasive test that measures the ratio of 13CO2 to 12CO2 in patients’ breath samples to detect the presence of urease associated with H. pylori as an aid to diagnose infection, and to confirm that H. pylori infection has been eradicated after antibiotic therapy.
Specifically, patients who took PPIs within the last 2 weeks can still be tested but the result needs to be interpreted with caution. The recommendation still stands that patients should not take antimicrobials, PPIs, and bismuth preparations within 2 weeks prior to testing.
For patients that took PPIs within 2 weeks of testing, appropriate action can be taken after obtaining a positive result. But if a negative result occurs, the test should be repeated 2 weeks after discontinuing PPI use.
The approval of the label update is based on clinical studies that evaluated the effects of PPI use on the UBT method in patients taking the test. Patients may now be tested for initial H. Pylori infection without discontinuing PPIs, which can allow for earlier detection and treatment.
For more information call (800) 441-6763 or visit Otsuka-US.com.